Catalog No.
VVV07903
Species reactivity
Nipah virus (NiV)
Host species
Human
Isotype
IgG1
Clonality
Monoclonal
Target
Glycoprotein G, G
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9IH62
Applications
ELISA, Neutralization
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA2191
Design and Preliminary Immunogenicity Evaluation of Nipah Virus Glycoprotein G Epitope-Based Peptide Vaccine in Mice., PMID:40333318
A monoclonal antibody targeting the Nipah virus fusion glycoprotein apex imparts protection from disease., PMID:39240113
An in vivo BSL-2 model for henipavirus infection based on bioluminescence imaging of recombinant Cedar virus replication in mice., PMID:38770087
Computer-assisted identification of potential quinolone derivatives targeting Nipah virus glycoprotein attachment with human cell surface receptor ephrin-B2: Multistep virtual screening., PMID:37442011
Assessment of the immunogenicity and protection of a Nipah virus soluble G vaccine candidate in mice and pigs., PMID:36274696
Computational Identification of Potential Multitarget Inhibitors of Nipah Virus by Molecular Docking and Molecular Dynamics., PMID:35744699
Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates., PMID:34696372
Lentiviral Vector Pseudotypes: Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene Therapy., PMID:32933033
Epitope-Based Peptide Vaccine against Glycoprotein G of Nipah Henipavirus Using Immunoinformatics Approaches., PMID:32377531
Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study., PMID:32027842
A Cross-Reactive Humanized Monoclonal Antibody Targeting Fusion Glycoprotein Function Protects Ferrets Against Lethal Nipah Virus and Hendra Virus Infection., PMID:31686101
Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities., PMID:30866781
Generation of therapeutic antisera for emerging viral infections., PMID:30323953
Two highly similar LAEDDTNAQKT and LTDKIGTEI epitopes in G glycoprotein may be useful for effective epitope based vaccine design against pathogenic Henipavirus., PMID:26970211
Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection., PMID:25392218
Characterization of a third generation lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell transduction., PMID:23698741
Nipah virus envelope-pseudotyped lentiviruses efficiently target ephrinB2-positive stem cell populations in vitro and bypass the liver sink when administered in vivo., PMID:23192877
Nipah virus infection and glycoprotein targeting in endothelial cells., PMID:21054904
A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection., PMID:19888339
Ephrin-B2 expression critically influences Nipah virus infection independent of its cytoplasmic tail., PMID:19108727
Evidence of a potential receptor-binding site on the Nipah virus G protein (NiV-G): identification of globular head residues with a role in fusion promotion and their localization on an NiV-G structural model., PMID:16840334
Henipaviruses: recent observations on regulation of transcription and the nature of the cell receptor., PMID:15119767
For research use only. Not for human or drug use.
